AU2022270331A1 - Urolithin for increasing stem cell function - Google Patents

Urolithin for increasing stem cell function Download PDF

Info

Publication number
AU2022270331A1
AU2022270331A1 AU2022270331A AU2022270331A AU2022270331A1 AU 2022270331 A1 AU2022270331 A1 AU 2022270331A1 AU 2022270331 A AU2022270331 A AU 2022270331A AU 2022270331 A AU2022270331 A AU 2022270331A AU 2022270331 A1 AU2022270331 A1 AU 2022270331A1
Authority
AU
Australia
Prior art keywords
urolithin
cells
population
stem cell
hspcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022270331A
Other languages
English (en)
Other versions
AU2022270331A9 (en
Inventor
Mukul Girotra
Nicola Vannini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Ludwig Institute for Cancer Research Ltd
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Ludwig Institute for Cancer Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA, Ludwig Institute for Cancer Research Ltd filed Critical Societe des Produits Nestle SA
Publication of AU2022270331A1 publication Critical patent/AU2022270331A1/en
Publication of AU2022270331A9 publication Critical patent/AU2022270331A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Primary Cells (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022270331A 2021-05-05 2022-05-02 Urolithin for increasing stem cell function Pending AU2022270331A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21172290 2021-05-05
EP21172290.5 2021-05-05
PCT/EP2022/061666 WO2022233767A1 (en) 2021-05-05 2022-05-02 Urolithin for increasing stem cell function

Publications (2)

Publication Number Publication Date
AU2022270331A1 true AU2022270331A1 (en) 2023-10-12
AU2022270331A9 AU2022270331A9 (en) 2023-10-19

Family

ID=75825544

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022270331A Pending AU2022270331A1 (en) 2021-05-05 2022-05-02 Urolithin for increasing stem cell function

Country Status (8)

Country Link
US (1) US20240228966A1 (https=)
EP (1) EP4333832A1 (https=)
JP (1) JP2024516187A (https=)
CN (1) CN117202903A (https=)
AU (1) AU2022270331A1 (https=)
BR (1) BR112023022224A2 (https=)
CA (1) CA3213384A1 (https=)
WO (1) WO2022233767A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998005635A1 (en) 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
WO2019163176A1 (ja) * 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤
JP7557374B2 (ja) * 2018-04-30 2024-09-27 アマゼンティス エスアー 免疫増強剤としてのウロリチンａ
JP7677893B2 (ja) * 2019-01-18 2025-05-15 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 幹細胞機能を向上させるための薬剤及び方法

Also Published As

Publication number Publication date
EP4333832A1 (en) 2024-03-13
CN117202903A (zh) 2023-12-08
US20240228966A1 (en) 2024-07-11
WO2022233767A1 (en) 2022-11-10
CA3213384A1 (en) 2022-11-10
JP2024516187A (ja) 2024-04-12
BR112023022224A2 (pt) 2024-02-06
AU2022270331A9 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
AU2020209429B2 (en) Agents and methods for increasing stem cell function
Brosseau et al. Prebiotic supplementation during pregnancy modifies the gut microbiota and increases metabolites in amniotic fluid, driving a tolerogenic environment in utero
Yu et al. L-Arginine-Dependent epigenetic regulation of interleukin-10, but not transforming growth factor-β, production by neonatal regulatory T lymphocytes
US20240390425A1 (en) Rejuvenated aged hematopoietic stem cells and methods of use
US20240010981A1 (en) Compositions and methods for increasing stem cell function
US20230365933A1 (en) Compositions and methods for increasing stem cell function
JP7295810B2 (ja) 移植に適した臍帯細胞画分の選択と使用
US20240228966A1 (en) Urolithin for increasing stem cell function
WO2020096672A1 (en) Use of lactoferrin for generating myeloid-derived suppressor cells
HK40104930A (zh) 用於增加干细胞功能的尿石素
HK40058827A (en) Agents and methods for increasing stem cell function
HK40096626A (zh) 用於增加干细胞功能的组合物和方法
HK40095240A (zh) 用於增加干细胞功能的组合物和方法
Filip et al. Homing of lin−/CD117+ hematopoietic stem cells
JP2010509360A (ja) 幹細胞移植を補助するためにＡＬＤＨｂｒ細胞を使用する方法
THEILER Role of Short Chain Fatty Acids (SCFA) in Allergic Inflammation
Imanirad et al. HIF1α is a regulator of hematopoietic progenitor and stem cell development
Ngu The influence of diet-induced obesity and exercise on bone marrow extracellular vesicles in an irradiated mouse model
WO2025160465A1 (en) A method of treating signs or symptoms of the aging process
Chandrinou et al. Publication only EBMT 2006
Gövert A functional characterisation of the Transplant Acceptance-Inducing Cell

Legal Events

Date Code Title Description
SREP Specification republished